The recent developments of tau-positron emission tomography (tau-PET) enablein vivo assessment of neuropathological tau aggregates.Among the tau-specific tracers, the application of11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) inPET shows high sensitivity to Alzheimer disease (AD)-related tau deposition.The current study investigates the regional tau load in patients within theAD continuum, biomarker-negative individuals (BN) and patients withsuspected non-AD pathophysiology (SNAP) using 11C-PBB3-PET. Here, MAPT is linked to Alzheimer disease.